AI 对冲基金 · 大师信号(存档)

The inflection is real and it's getting steeper. TTM revenue growth went from 32% in 2025/Q1 to 36%, 48%, then 63% and 62% in the last two prints. Operating margin has moved from -48% to -25%, and gross margin from 29% to 36%, so this is operating leverage showing up, not just top-line noise. The balance sheet was the thing that could have blown this up, and it's been fixed: D/E went from 2.10 to 0.20, the current ratio is 5.48, and BVPS rose from 0.64 to 5.84, though largely through equity raises and dilution. The bear case is price. At a 41.3B market cap with ROE still -8% and FCF/share at -0.18 and deteriorating, the market is already paying for a lot of the future. So this is a trend-following long at sensible size, not a fat pitch. As long as growth holds above 50% and the margin path keeps compressing losses, I stay with it. Any rollover in that growth rate and I'm out fast.

This is a business that has never earned a dime for its owners in the record I'm shown. ROE has averaged -29% and net margin -35%, and free cash flow per share is still negative at -0.18. I'll grant real progress: gross margin climbed from 27% to 36%, revenue is growing 62%, and debt/equity fell from 2.10 to 0.20 with a 5.48 current ratio. But much of that balance-sheet repair came from issuing stock, not from earnings. Book value per share jumping from 0.64 to 5.84 while EPS stays negative tells me owners are being diluted to fund the losses. At a $41.3 billion market cap and a P/E of -256, the price already assumes a future of wonderful economics that the numbers haven't yet shown, and I don't pay for hope.

Invert it: this business has never shown a profit anywhere in the record. Operating margin is still -25%, net margin -21%, ROE -8%, and free cash flow is -$0.18 a share. The trend is real, I'll grant: gross margin rose from 27% to 36%, revenue grows about 62%, and debt/equity fell from 2.10 to 0.20. But book value per share jumping from $0.64 to $5.84 while the company loses money looks like new equity raised to feed the furnace, not earnings compounding. A $41.3B market cap on a P/E of -256 asks you to believe a spectacular future that the numbers haven't begun to prove. I'd rather miss this one than pay a silly price for hope, so it's a pass, bordering on a firm no.

This is a story stock, not an earnings stock. Revenue is growing fast, 62% in the latest twelve months and 36-121% before that, and gross margin has climbed from 27% to 36%. That's the part of the story that checks out. But there are no earnings to put a PEG on: EPS is still -$0.08, the operating margin is -25%, free cash flow is -$0.18 a share, and the P/E is -256 on a $41.3B market cap. The balance sheet has improved a lot, with D/E falling from 2.10 to 0.20 and the current ratio at 5.48. Book value per share jumped from $0.64 to $5.84, which looks like new equity coming in, and that means dilution rather than earned book. Paying $41B for a turnaround that hasn't turned yet is paying for the dream, and that's how people lose money.

This enterprise has not earned a profit in any period shown. Trailing net margin is -21% and ROE -8%, and free cash flow is negative in every period, -0.18 per share at present. The balance sheet has improved: the current ratio is 5.48 and debt/equity has fallen from 2.10 to 0.20. But much of that strength appears to come from new capital; book value per share rose from 0.64 to 5.84 while earnings stayed negative. A market capitalization of 41.3B against a negative P/E of -255.89 and book value of just 5.84 per share capitalizes hope, not demonstrated earning power. Revenue growth of 62% counts for little with a defensive investor when no dollar of it has yet reached the bottom line. There is no margin of safety here, only a large premium for a future the record does not yet support.

The economics here are extraordinary. Return on equity has averaged 1.13 and stood at 1.17 in the latest period. Gross margins have held around 0.75, operating margins sit at 0.66, and book value per share has compounded from 3.29 to 9.50 in about eighteen months. The balance sheet is sound, with debt/equity of 0.40 and a current ratio of 4.59, and revenue is still growing 106% a year. At 28 times earnings, the price is not a bargain for a $5.4 trillion company, but it is a fair price for a wonderful business, not a price that demands perfection. My hesitations are real, though. Semiconductors sit at the edge of my circle of competence, and a boom this steep invites a cyclical hangover. Free cash flow per share was only 0.89 against EPS of 2.48 in the latest quarter. The 0.71 net margin in the prior quarter also looks inflated by non-operating items. So I would own it, but not bet the farm on ten more years like the last two.

Invert first. What kills this is a spending cycle that turns, and there is some evidence to watch. The latest quarter's free cash flow was $0.89 per share against $2.48 of EPS, so cash conversion was poor. Net margin of 0.71 beat operating margin of 0.66 in 2027/Q1, which points to non-operating gains flattering results. Debt/equity has crept up from 0.31 to 0.40. But look at the whole run. ROE has stayed above 1.0 in every period, gross margins sit around 0.75, operating margins run 0.60–0.66, and book value per share has compounded roughly 74% a year, from $2.73 to $9.50. That is a real machine, not a one-year fluke. At 28x earnings with revenue up 106%, you are not paying a silly price for that quality, so I lean bullish. I'd hold back from full conviction because cyclicality and that weak recent cash conversion are real risks.

This is a fast grower, not a stalwart. Latest-quarter EPS was $2.48 against $1.10 a year ago, up about 125%, and revenue growth was 106%. At a 28.41 P/E that works out to a PEG around 0.3, and on any fair reading of that growth the price doesn't bake it in. The story checks out: gross margin is holding at 0.75, operating margin is 0.66, ROE is 1.17, and debt/equity is a modest 0.40 with a 4.59 current ratio. I do see yellow flags. Sequential EPS barely moved ($2.42 to $2.48), net margin eased from 0.71 to 0.62, and FCF per share fell to $0.89 from $2.02. At a $5.4 trillion market cap, doubling again is a tall order. Still, the earnings keep marching, and you're not paying a story price for them.

Revenue growth is accelerating: 56%, 62%, 73%, 85% and now 106% over the last five periods. A second leg of acceleration at a $5.4T market cap is exactly the kind of inflection I pay for. Operating margin has climbed from 49% to 66% and gross margin holds at 75%. EPS went from $1.10 to $1.32, $1.78, $2.42 and now $2.48, roughly 8.0 on a trailing basis against a 28x multiple. That is not a price that assumes the business doubles, so the trend disagrees with the multiple and the asymmetry favors the long side. The blemishes are real but not thesis-breaking. FCF/share fell to $0.89 from $2.02, far below EPS, which points to cash going into working capital. D/E ticked up from 0.33 to 0.40, and net margin came off the 71% print, which looks one-off. Watch cash conversion closely, but acceleration plus margin expansion at 28x is a swing, not a pass.

The enterprise itself is formidable. The current ratio is 4.59, debt to equity only 0.40, and net margins have run near 0.56-0.71 with positive earnings in every period shown, so financial strength and earnings stability pass without question. Price is another matter. At a P/E of 28.41, trailing earnings of roughly $8.00 per share (the last four quarters: 2.48 + 2.42 + 1.78 + 1.32) imply a price near $227. Against book value of $9.50 per share, that is roughly 24 times book, and P/E times P/B comes to about 680 against my ceiling of 22.5. The record is also short, only about two years of trailing periods, while revenue growth of 106% and book value compounding at 74% a year are exactly the growth a prudent man should refuse to capitalize. Sound business, strong balance sheet, but no margin of safety at all: this price rests on hope, not demonstrated value, and overvaluation is itself a bearish fact.

The inflection is in the latest quarter. Q4 gross margin jumped to 17% from 10% in Q3 and 6% in Q2. Operating margin went to 13% and net margin to 11%, and quarterly EPS of $1.79 was more than Q3's $0.74 and Q2's $0.61 combined. On the full year, revenue grew 78% and EPS more than doubled to $3.40 from $1.60, yet the stock trades at 12.6x earnings. That multiple prices this like a low-margin box-pusher, not a business whose margins just rose sharply. The bear case is real: FY free cash flow was -$10.61 a share and Q3 alone burned $10.19. D/E is still 1.07, though it has come down from 3.00 in Q2. BVPS nearly doubling in one quarter (11.53 to 22.04) points to something beyond earnings, possibly new equity, which the data doesn't explain. Revenue growth is also cooling from 123% to 93%, and one quarter of 17% gross margin could be mix rather than a new baseline. Still, EPS is accelerating, the balance sheet is deleveraging and Q4 FCF turned positive at $1.09 a share, which makes this asymmetric enough to own, sized so I can add if Q1 confirms the margin step-up.

This is a fast grower by any measure. Revenue grew 78% for FY2026 and EPS jumped from $1.60 to $3.40, more than doubling. At a 12.6 P/E against growth like that, the PEG is a fraction of 1, which is the kind of number I go looking for. What keeps me from pounding the table is the quality of those earnings. Free cash flow was -$10.61 a share for the year while EPS was +$3.40, so the growth is eating cash, probably in inventory and receivables. Debt/equity swung from 0.56 up to 3.00 and back to 1.07, and book value per share nearly doubled in one quarter (11.53 to 22.04), which looks like outside capital coming in rather than earnings piling up. Margins are thin: net margin runs 3-6% on most quarters, and the fiscal-year gross margin is 11% versus 13% at the oldest quarter. Q4's 17% gross margin and $1.79 EPS are encouraging, but it's one quarter. The price is cheap enough to own the story, but I'd keep the position small until the cash flow catches up with the earnings.

At a P/E of 12.61 on trailing EPS of $3.40, the implied price is about $43 against book of $22.04, roughly 1.95 times book. The product of multiplier and price-to-book, about 24.6, sits just above my 22.5 ceiling, so the margin of safety is thin, not absent. Earnings stayed positive in every period shown and the current ratio of 3.87 is comfortable. But debt-to-equity of 1.07 is more than I call modest, and it reached 3.00 only two quarters ago. Free cash flow of -$10.61 per share for the year means the reported profits are not arriving as cash, and a net margin of about 5% on revenue up 78% has the look of a boom rather than steady earning power. Book value per share nearly doubled in one quarter, from $11.53 to $22.04, which suggests fresh capital rather than retained earnings. This is a real enterprise at a price that is not extravagant, but its stability and cash generation are not yet proven, so I remain neutral.

This is a server assembler earning an 11% gross margin and a 6% net margin, and a trend of -0.02 in gross margin says it has no pricing power. That is a commodity business, not a franchise with a moat. Revenue grew 78% in FY2026, but free cash flow was -$10.61 per share against EPS of $3.40, so the growth is eating cash rather than producing it. Debt-to-equity swung from 0.56 to 3.00 and back to 1.07, and book value per share nearly doubled in one quarter, from $11.53 to $22.04. That pattern looks more like financing activity than steady compounding, and it isn't the balance sheet of an owner I can count on. A P/E of 12.6 and an ROE of 27% look cheap on paper, but a fair business at a cheap price that burns cash is not something I'd want to hold for ten years.

Invert: this is a thin-margin assembler, not a franchise. Gross margin swung between 6% and 17% over the year and net margin averages only about 5%. FY2026 shows EPS of $3.40, yet free cash flow was -$10.61 per share, so revenue growth of 78% is eating capital rather than producing it. Reported earnings that don't turn into cash make me suspicious. Debt/equity went from 0.56 to 3.0 at mid-year before settling at 1.07. Book value per share jumped from $11.53 to $22.04 in a single quarter, which Q4 EPS of $1.79 cannot explain, so it looks like financing rather than compounding. A P/E of 12.6 looks cheap, but cheap is what you pay for a business with no pricing power that burns cash to grow.

This is the kind of inflection I pay up for. Revenue growth went from 35% in 2025/Q2 to 66%, then 198%, then 257% in the latest period, and it is still accelerating. Operating margin expanded from 41% to 76% and gross margin from 54% to 83% over the same stretch. EPS of 12,886 in 2026/Q2 is more than double the 5,535 a quarter earlier, and FCF/share jumped to 7,448. Leverage is falling rather than rising: D/E dropped from 0.66 to 0.33 and the current ratio is 2.59, so there is no blow-up risk while the trend runs. A 25x P/E on earnings compounding this fast does not look like a market that has recognized the trajectory. My caveats: 83% gross margins are extreme, and a net margin of 118% points to non-operating gains that I will not capitalize. The top of a cycle can look like this too, but the second derivative is still positive, so I stay long and watch for the first deceleration.

This is a remarkable run of numbers. Book value per share went from 8,959 to 36,041 in about two years, ROE reached 0.93, gross margin reached 0.83, debt/equity fell from 0.66 to 0.33 and the current ratio is a sturdy 2.59, so the balance sheet has been handled sensibly. But this is a memory chip business, and its figures bounce the way a commodity's do. Revenue growth swung from 0.35 to 2.57. The latest net margin of 1.18 exceeds revenue, which tells me non-operating items or accounting quirks are muddying the picture, and I can't fully understand it from what's here. Gross margins were 0.48–0.57 just a year or two ago, so I can't call today's 0.83 a durable moat rather than a cyclical peak. At a 25 P/E on what may be peak earnings, roughly 9x book, and a 1,385B market cap, the price assumes the good times last. I'd admire it from the sidelines rather than buy it here.

On the surface the numbers are dazzling. Latest EPS is 12,886 against 5,892 for FY2025, revenue growth is 257%, and at a 25.22 P/E the PEG works out well under 1. The balance sheet has also gotten stronger: debt/equity fell from 0.62 to 0.33 and the current ratio sits at 2.59. But I'd put this company in the cyclical bucket, not the fast-grower bucket. Operating margin went from 0.40 to 0.76 in two years, and a net margin of 1.18 means profit exceeded revenue, which points to non-recurring gains inflating that EPS. With cyclicals you get burned buying at peak margins on what looks like a cheap multiple, and I can't tell from these numbers how long this boom lasts. It's a strong company at what looks like the top of its cycle, so I'm staying neutral.

The balance sheet is beyond reproach: a current ratio of 2.59 and debt/equity of only 0.33 would satisfy any defensive investor. But the price does not. At a P/E of 25.2 on trailing EPS of 12,886, the implied price is roughly 325,000, about 9 times book value of 36,041 per share, far outside my limits of 15 times earnings and 1.5 times book. Those earnings are also peak-cycle results. Trailing EPS has more than doubled from 5,535 in a single quarter, and a net margin of 1.18, which exceeds revenue, points to non-recurring items rather than repeatable earning power. Earnings have stayed positive throughout the record, but swings this violent in a cyclical business capitalize hope, not demonstrated results, so the security fails my margin-of-safety test despite its financial strength.

The inflection is real and it's holding. TTM revenue growth went from 12-13% in early FY25 to 18% for five straight quarters, with full-year growth moving from 15% to 18%. EPS jumped from 13.71 to 18.01, about 31%, and the Q4 print of 4.82 against 3.67 a year ago confirms it isn't just the one-off-looking Q2 (47% net margin). At 27.3x earnings with 30%+ EPS growth on a $3.7T base, the market is paying a growth multiple, not an acceleration multiple, so the price hasn't fully caught up. What keeps me from swinging with maximum size is spending: FCF/share slipped from 9.64 to 9.02 while earnings rose 31%. Gross margin also eased from 69% to 67-68%, and TTM operating margin came in from 49% in Q1 to 45% in Q4. Leverage is tame at 0.71 D/E, so there's no blow-up risk, but I want to see that capex convert to cash before pressing harder.

This is a wonderful business by any measure I use. ROE has held at 32-36% across every period shown, net margins run about 40%, revenue is still growing 18%, and book value per share has compounded at 21%, from $38.75 to $59.58 in under two years. What gives me pause is the gap between reported earnings and owner earnings. EPS rose to $18.01, yet free cash flow per share fell to $9.02 from $9.64, so only about half of reported profit is showing up as cash the owners could take out. Gross margin has also slipped a point, from 0.69 to 0.68, which suggests heavy reinvestment whose returns are not yet proven in the numbers. At 27.3 times earnings and a $3.675 trillion market cap, the stock yields roughly 3.7% on earnings but under 2% on free cash flow. That is a full price for a great company, not a fair one, so I'd happily own it but wouldn't reach for it here.

The quality of this business is plain to see. ROE has held at 0.32-0.36 in every period, operating margins have stayed around 0.45-0.49, revenue is growing 18%, and book value per share has compounded at 21% while debt/equity fell from 0.82 to 0.71. But invert it and look at the cash. FY EPS rose from 13.71 to 18.01, yet FCF per share fell from 9.64 to 9.02, so barely half of reported earnings shows up as free cash. A business that used to throw off cash is now swallowing capital, and that can't be waved away. The Q2 net margin of 0.47 also looks like a one-off that flatters the EPS jump. At 27.3x earnings the price looks fair, but at roughly 55x free cash flow you have to believe the heavy reinvestment will earn the old returns. A great business at a price I won't cheer for is a pass for now, not a sale.

This is a giant that's growing like a fast grower. Revenue growth sped up to 18% from 15%, and full-year EPS jumped from 13.71 to 18.01, about 31%. But that Q2 quarter with a 47% net margin looks like a one-time boost, since the other quarters ran 36-40%. Strip it out and underlying earnings growth is closer to the low-to-mid 20s, so a 27.3 P/E gives a PEG of roughly 1. That's a fair price, not the bargain I look for. The balance sheet is fine at 0.71 debt/equity. What bothers me is that free cash flow per share slipped from 9.64 to 9.02 while earnings soared, so the cash isn't following the profits. Great company, fully priced, and I'd want the cash flow to catch up before paying more.

This is an enterprise of undeniable quality. Earnings run positive in every period shown, net margins sit at 36-40%, return on equity holds near 0.34, and full-year EPS rose from 13.71 to 18.01. But quality is not a margin of safety. At a P/E of 27.3 the implied price is about $492 a share, roughly 8.3 times book value of $59.58, and nearly three times the ~$155 my 22.5 multiple of earnings times book would permit. The balance sheet also fails my defensive test: the current ratio of 1.23 has slipped from 1.40 and is well short of 1.5, even though debt to equity has improved to a tolerable 0.71. Free cash flow of $9.02 a share covers only half of reported EPS of $18.01, so the buyer is paying for projected growth rather than demonstrated cash earning power. A sound business at a speculative price is a poor purchase for the defensive investor.

The top line has turned. Revenue growth went from -34% for FY2025 and -18% in the late-2025 quarters to +199% in Q1 and +185% in Q2 2026. Gross margin rose from 0.21 in 2025/Q3 to 0.43 now, so the business side is moving the right way. But the base is tiny. Operating margin is still -546% of revenue, EPS has swung back to -0.16 from +0.10, and the net-margin swings look like non-operating noise rather than earnings power. A $5.3B market cap already prices in a big part of that acceleration. The balance sheet is also moving the wrong way: the current ratio fell from 37 to 3.94, D/E doubled to 0.21 and BVPS slipped from 1.75 to 1.61, so the cash cushion is shrinking while the burn continues. There is a real inflection, but the price already knows it and the losses are still enormous, so I don't see the asymmetry to swing either way.

I can't put this company in any of my categories: it's no fast grower, no stalwart, and there's no turnaround either, because there are no earnings to turn. The operating margin is -546% and the net margin is -1024% on a trailing basis. EPS of -0.16 gives a P/E of -19.5, so there's no growth rate for a PEG test, and you're paying $5.3B purely for a story. Revenue did bounce 185% lately, but that comes after years of declines (-34% for FY2025, -52% TTM in Q1'25), and free cash flow is still negative every period (-0.08/share). The balance sheet is the one bright spot, with D/E at 0.21 and a current ratio of 3.94, though book value per share growth has come mostly from issuing stock, not from earnings. A hot-story valuation on a business with no visible earnings is exactly how people lose money.

An investment requires demonstrated earning power, and this enterprise has none. Trailing EPS is -0.16, the operating margin is -546% of revenue, the average net margin is -23.14, the average ROE is -0.90, and free cash flow per share has been negative in every period shown. The balance sheet is the one respectable feature: the current ratio is 3.94 and debt to equity is 0.21. But that liquidity largely reflects capital raised from shareholders rather than earnings retained. At a 5.3B market capitalization with no profits and repeated losses, the price capitalizes hope in the technology rather than results. There is no margin of safety, and the price is speculative.

This is a business I can't value, and the numbers explain why. Operating margins run about -5.5x to -14.7x revenue, and net margin averages -23x. ROE has been negative every period, averaging -0.90, and free cash flow per share is negative throughout (-0.23 for FY2025). The rise in book value per share from 0.37 to 1.61 came from selling stock, not from earnings, so owners are being diluted rather than compounded. The balance sheet does have liquidity (current ratio 3.94, D/E 0.21), but the current ratio has already fallen from 41.57. A $5.3B market cap on a company that loses many dollars for every dollar of sales demands perfection. I'd pass without hesitation.

Invert it: this business has never made a dime from operations in the data shown. Operating margins run from -5.5x to -14.7x revenue, meaning the company spends five to fifteen dollars for every dollar it takes in. ROE has been negative in every period, averaging -0.90. The book value 'compounding' at a 0.93 CAGR is share issuance dressed up as growth. It is not retained earnings. Free cash flow per share is negative in every period, and the occasional positive net margin (7.52 in 2026/Q1, 28.95 in 2025/Q1) looks like non-operating noise rather than business quality. Paying 5.3B for a cash-consuming venture with negative EPS of -0.16 and gross margins that have slipped over the period requires believing something heroic, and I don't pay for heroics.

The top line has turned. Revenue growth went from -3% at FY25 to +16% and now +26%, and I don't dismiss that. But none of it is reaching profit. Operating margin has collapsed from 11% in 2024/Q3 to 1% now, and gross margin slipped from 21% to 17% in a single quarter. Free cash flow per share swung from +0.37 to -0.28. That looks like growth bought with price cuts or spending, not operating leverage. Latest EPS of 0.29 is flat against 0.30 a year ago, FY25 EPS of 0.98 roughly halved from 1.81, and ROE has sunk from 21% to 5%, yet the stock trades at 344x earnings on a $1.45T cap. Leverage at 0.70 D/E isn't a blow-up risk, but the price already assumes a margin recovery the trend is actively contradicting, so the asymmetry runs the wrong way.

I don't see a moat in these numbers. ROE has slid from 0.21 in 2024/Q3 to 0.05 today, operating margin has shrunk from 0.11 to 0.01, and gross margin has drifted down to 0.17. That reads like a business losing pricing power, not one holding it. The balance sheet is serviceable, with a current ratio of 1.94, but debt/equity has crept up to 0.70. Free cash flow per share has turned negative at -0.28 on a trailing basis, which is not what I want to see from a company asking to be valued at $1.45 trillion. Paying 344 times earnings for a business earning a 4% net margin demands perfection piled on hope, and I'd rather pass.

Invert it: what kills this investment? Paying 344 times earnings for a business whose returns and margins are shrinking. ROE fell from 0.21 in 2024/Q3 to 0.05 today, and operating margin went from 0.11 to 0.01. TTM FCF per share is now negative at -0.28, down from 1.57 at 2025/FY, and gross margin has slid to 0.17. Book value compounding at about 10% a year is respectable, but it doesn't come close to justifying a $1.45 trillion market cap on a 4% net margin. To own this at this price you have to believe in something the numbers don't show, and that is the definition of a stupid price.

At a market capitalization of 1454.3B and a P/E of 344, the price rests on hope rather than on demonstrated earning power. Trailing quarterly EPS of 0.29, 0.12, 0.22 and 0.35 sum to roughly 0.98, which puts the implied price near 337 against book value of 22.16 per share, or about fifteen times book. No margin of safety exists. The balance sheet is respectable, with a current ratio of 1.94 and debt/equity of 0.70, but that is a floor, not a justification. The earnings record is deteriorating: ROE has fallen from 0.21 to 0.05, operating margin from 0.11 to 0.01, full-year EPS from 1.81 to 0.98, and the latest free cash flow per share is negative at -0.28. The defensive investor pays for results already achieved, not projected growth, and here overvaluation is the decisive bearish fact.

The P/E is 344 on earnings that have been shrinking. EPS fell from $1.81 in FY2024 to $0.98 in FY2025, and I can't find a growth rate anywhere near 344 to justify that multiple. The PEG is off the charts. Revenue did pick up to 26% growth this quarter, but it isn't reaching the bottom line: operating margin is down to 1%, gross margin slipped from 0.20 to 0.17, and free cash flow per share turned negative at -$0.28. The balance sheet is fine, with a current ratio of 1.94 and debt/equity of 0.70. Still, a $1.45 trillion market cap on a 4% net margin and 5% ROE is a hot-story price on cooling numbers, and that's how people lose money.

This is an inflection, not a plateau. TTM revenue growth dipped to 20% in 2025/Q4, then reaccelerated to 32%, 35% and 36%. Margins are expanding hard on top of that: gross margin went from 59% to 68% and operating margin from 50% to 60% in four quarters. Quarterly EPS went from 76.64 a year ago to 136.27, roughly +78%, with sequential steps of 93.54, 110.44 and 136.27, so momentum is building rather than fading. A 32.6x P/E on a $2.26T cap is not cheap, but it rests on trailing earnings that are compounding this fast, and the balance sheet is clean (D/E 0.45, current ratio 2.46), so there's no blow-up risk here. The things to watch are FCF/share, which is lumpy and well below EPS (53.02 vs 136.27, most likely heavy capex), and the size of the cap. Those argue for sizing with some discipline, not for standing aside.

This is a fast grower, even at a 2,256B market cap. Quarterly EPS went from 76.64 in 2025/Q2 to 136.27 now, about 78% year over year, and full-year EPS rose from 223.18 to 326.83, about 46%. Revenue is growing 36% and net margin widened from 0.43 to 0.56, so the sales growth is showing up in earnings. A P/E of 32.63 against 45-75% earnings growth puts the PEG around 0.5-0.7, which means I'm not paying for a story. Debt/equity is a modest 0.45, the current ratio is 2.46 and book value is compounding at 24%. My worries are that free cash flow per share (53.02 this quarter) trails earnings badly, so it's capital-hungry, and a company this big with margins at a peak can't keep growing like this forever. If growth cools, that multiple won't look cheap.

This is a superb business by the numbers. ROE has climbed from 0.29 to 0.40, gross margin has expanded from 0.58 to 0.68, and operating margin has risen from 0.47 to 0.60. Book value per share has compounded at about 24% while debt/equity fell from 0.56 to 0.45. Invert it, though. Trailing EPS is roughly 427, but trailing FCF per share is only about 217, so half the earnings go straight back into capital spending. That is a hungry business, not a royalty. You're paying 32.6x earnings for a semiconductor manufacturer at record margins, and that price requires believing today's peak economics persist. It's a wonderful company at a full price, so I'll watch rather than chase it.

As an enterprise, this company passes my tests handsomely. The current ratio is 2.46 and debt to equity a modest 0.45. Earnings have been positive and rising in every period shown, with quarterly EPS climbing from 62.68 to 136.27. Book value per share has compounded at about 24% a year to 1,248.33, and ROE has reached 0.40. The price is another matter. At a P/E of 32.63 on a 2,256.1B market capitalization, the buyer pays more than double my ceiling of 15. The price also runs to many multiples of book value, far beyond any reasonable reading of the 22.5 limit on P/E times P/B. Such a valuation assumes that 56% net margins and 36% revenue growth will persist, which is a projection rather than a demonstrated floor. Free cash flow per share of 53.02 is well below the quarter's EPS, which argues for caution. This is a sound business offering no margin of safety, so the defensive investor should admire it and wait.

This is a wonderful business on the numbers. ROE has climbed from 0.29 to 0.40 over two years, gross margin widened from 0.58 to 0.68, and net margin now runs at 0.56, which tells me it has real pricing power. The balance sheet is sound too: debt/equity fell from 0.56 to 0.45, the current ratio is 2.46, and book value per share compounded at about 24%, rising from 775 to 1,248. What gives me pause is the cash. FY2025 free cash flow was 191 per share against EPS of 327, because this business has to keep pouring money into plants to stay ahead, and chipmaking has always been cyclical. At 32.6 times earnings and a $2.26 trillion market cap, the price assumes today's 36% revenue growth and record margins will last, so I'd admire this one from the sidelines and wait for a fairer price.